Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib

Simple item page
dc.contributor.authorInanc N.
dc.contributor.authorAbacar K.Y.
dc.contributor.authorOzturk M.A.
dc.contributor.authorTufan A.
dc.contributor.authorKaradeniz H.
dc.contributor.authorSari I.
dc.contributor.authorCan G.
dc.contributor.authorErez Y.
dc.contributor.authorPehlivan Y.
dc.contributor.authorDalkilic H.E.
dc.contributor.authorOcak T.
dc.contributor.authorCefle A.
dc.contributor.authorYazici A.
dc.contributor.authorSenel A.S.
dc.contributor.authorAkar S.
dc.contributor.authorDurak-Ediboǧlu E.
dc.contributor.authorKoca S.S.
dc.contributor.authorPiskin-Sagir R.
dc.contributor.authorYilmaz S.
dc.contributor.authorGulcemal S.
dc.contributor.authorSoysal-Gunduz O.
dc.contributor.authorBasibuyuk C.S.
dc.contributor.authorAlkan S.
dc.contributor.authorCesur T.Y.
dc.contributor.authorOnen F.
dc.date.accessioned2024-07-22T08:02:11Z
dc.date.available2024-07-22T08:02:11Z
dc.date.issued2023
dc.description.abstractObjective To determine the rate of unintentional monotherapy (UM; switching to monotherapy from combination therapy of patients' own volition) in rheumatoid arthritis patients receiving tofacitinib and to evaluate tofacitinib survival rate. Methods This national, multicenter study included patients' data from the TURKBIO Registry. Demographics, clinical characteristics, disease duration and activity, comorbidities, and treatments were analyzed. Results Data of 231 rheumatoid arthritis patients (84.8% female, median age, 56 years) were included; 153 were initially prescribed combination therapy and continued to their therapies; 31 were initially prescribed combination therapy but switched to monotherapy on their own volition (UM); 21 were initially prescribed monotherapy and switched to combination therapy; 26 were initially prescribed monotherapy and continued to their therapies. The rate of comorbidities at the time of data retrieval was higher in the UM group than in the combination group (83.3% vs. 60.3%, p = 0.031). Presence of comorbidities was a significant factor affecting switching to monotherapy (p = 0.039; odds ratio, 3.29; 95% confidence interval, 1.06-10.18). The combination and UM groups did not differ regarding remission rate assessed by Disease Activity Score 28-joint count C-reactive protein (60.5% and 70%, respectively; p = 0.328). Drug survival rates of the UM and combination groups did not differ. The median drug survival duration of tofacitinib was 27+ months with 1- and 4-year drug survival rates of 89.6% and 60.2%, respectively, in the UM group. Conclusions Although 13.4% of the study population started monotherapy unintentionally, drug survival and remission rates of the UM and combination groups were not different. Comorbidity was a factor affecting transition from combination therapy to monotherapy. © Wolters Kluwer Health, Inc. All rights reserved.
dc.identifier.DOI-ID10.1097/RHU.0000000000002026
dc.identifier.issn10761608
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11759
dc.language.isoEnglish
dc.publisherLippincott Williams and Wilkins
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectArthritis, Rheumatoid
dc.subjectC-Reactive Protein
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPiperidines
dc.subjectSurvival Rate
dc.subjectC reactive protein
dc.subjectglucocorticoid
dc.subjectnonsteroid antiinflammatory agent
dc.subjectprednisolone
dc.subjecttofacitinib
dc.subjectC reactive protein
dc.subjectpiperidine derivative
dc.subjecttofacitinib
dc.subjectadult
dc.subjectArticle
dc.subjectclinical feature
dc.subjectcognition
dc.subjectcomorbidity
dc.subjectcontrolled study
dc.subjectDAS28
dc.subjectdemographics
dc.subjectdisease duration
dc.subjectfemale
dc.subjecthuman
dc.subjectinformation retrieval
dc.subjectKaplan Meier method
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectmonotherapy
dc.subjectmulticenter study
dc.subjectrheumatoid arthritis
dc.subjectsurvival rate
dc.subjectclinical trial
dc.subjectrheumatoid arthritis
dc.subjectsurvival rate
dc.titleUnintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
dc.typeArticle

Files

Collections

Scopus Koleksiyonu